Twist Bioscience Corp (TWST)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
The business works, the balance sheet carries no debt and the gross margin demonstrably climbed from 36.6 to 50.7 percent — there is no substance finding that threatens the company itself: no going concern warning, no negative equity, no interest burden. What remains open is the decisive operating question, and after twelve years it is still open: whether this revenue ever turns into profit. As long as selling and administration cost more than gross profit delivers, and the only progress on the loss line comes from a one-time sale, the turnaround is unproven — that is yellow, not green. Our view that the stock is expensive at 13 times revenue does not change the colour: price is not a quality attribute. The decision is yours.
symbol.quality_note
Twist Bioscience prints synthetic DNA onto a silicon chip, has grown at double-digit rates for years and has never posted a profitable fiscal year. In fiscal 2025 revenue rose 20 percent to $376.6 million and the gross margin climbed to 50.7 percent — yet the company still reported a $136.3 million operating loss, because selling and administrative expenses alone consumed $247.0 million. The net loss that shrank to $77.7 million contains a $48.8 million one-time gain from selling the data storage business, and in the first half of fiscal 2026 the loss grew again. We read the filings to the U.S. securities regulator, the SEC, line by line and work out where the money actually goes.
Read the analysis
Stock Watch
This analysis is as of July 26, 2026. Stock Watch will tell you what's changed at TWST since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 24 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 91.60 $ — 86% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
ThreatenedTwist verkauft keine KI-Produkte, sondern synthetische DNA — und benennt im Geschäftsbericht 2025 ausdrücklich, dass KI die Nachfrage nach bestimmten Formen der Gensynthese senken und die Branche umwälzen könnte; intern wird KI nur zur Effizienzsteigerung eingesetzt.
View the full file — quotes, sources, reviewed filings
„Further, while the impact that AI may have on the synthetic biology industry is still uncertain, recent advances in AI capabilities may indicate that it could be a significant disruptor in the synthetic biology industry. For example, AI may reduce customer demand for certain types of gene synthesis."
Zudem könnten die jüngsten Fortschritte bei den KI-Fähigkeiten darauf hindeuten, dass KI ein erheblicher Umwälzungsfaktor in der Branche der synthetischen Biologie sein könnte — auch wenn die Auswirkungen von KI auf diese Branche noch ungewiss sind. Zum Beispiel könnte KI die Kundennachfrage nach bestimmten Formen der Gensynthese verringern.
„In our ongoing efforts to innovate and optimize operational efficiency, we have integrated AI and machine learning into various aspects of our workplace. While AI and machine learning presents opportunities for enhanced productivity and innovation, it also introduces inherent risks, including legal and regulatory compliance risks and potential liability, that could adversely impact our business and reputation."
In unserem fortlaufenden Bemühen, Innovation und betriebliche Effizienz zu steigern, haben wir KI und maschinelles Lernen in verschiedene Bereiche unseres Arbeitsalltags eingebunden. KI und maschinelles Lernen eröffnen zwar Chancen für höhere Produktivität und Innovation, bringen aber auch immanente Risiken mit sich — darunter Risiken der Rechts- und Regulierungskonformität sowie mögliche Haftung —, die unserem Geschäft und unserem Ruf schaden könnten.
„Customers pursuing artificial intelligence (“AI”) enabled antibody discovery platforms may use Twist to generate not only the antibodies of interest but also comprehensive high quality characterization data that is critical for use in the development and refinement of algorithms and subsequently used for the identification of therapeutic antibody candidates with appropriate developability properties."
Kunden, die auf künstlicher Intelligenz („KI“) beruhende Plattformen zur Antikörper-Entdeckung verfolgen, können Twist nutzen, um nicht nur die gewünschten Antikörper zu erzeugen, sondern auch umfassende, hochwertige Charakterisierungsdaten, die für die Entwicklung und Verfeinerung von Algorithmen entscheidend sind und anschließend zur Identifizierung therapeutischer Antikörper-Kandidaten mit geeigneten Entwicklungseigenschaften verwendet werden.
Filings Reviewed: 10-Q 2026-05-04 · 10-Q 2026-02-02 · 10-K 2025-11-17 · 10-Q 2025-08-04 · 10-Q 2025-05-05 · 10-K 2024-11-18
Rated on July 26, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 1.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | -0.77 | -0.96 – -0.58 | 445 | 63.6% | 2 |
| 09/30/2027 | -0.85 | -2.05 – 0.11 | 520 | -10.4% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.50 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.53 | – | 89 | 24.10 | -35.60 | -21 | -24 |
| 2025: Q1 | -0.66 | – | 93 | 23.20 | -42.40 | -13 | -17 |
| 2025: Q2 | 0.33 | – | 96 | 17.90 | 21.20 | -1 | -11 |
| 2025: Q3 | -0.45 | – | 99 | 16.90 | -27.40 | -12 | -24 |
| 2025: Q4 | -0.50 | – | 104 | 16.90 | -29.40 | -25 | -35 |
| 2026: Q1 | -0.71 | – | 111 | 19.30 | -39.80 | -18 | -26 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2 | -44 | -44 | -2.35 | -39 | -77 | 76 |
| 2017 | 11 | -58 | -59 | -3.16 | -51 | -133 | 86 |
| 2018 | 25 | -71 | -71 | -2.68 | -66 | -201 | 116 |
| 2019 | 54 | -109 | -108 | -3.92 | -88 | 152 | 187 |
| 2020 | 90 | -140 | -140 | -3.57 | -142 | 336 | 399 |
| 2021 | 132 | -153 | -152 | -3.15 | -112 | 581 | 702 |
| 2022 | 204 | -249 | -218 | -4.04 | -124 | 789 | 961 |
| 2023 | 245 | -217 | -205 | -3.60 | -142 | 623 | 776 |
| 2024 | 313 | -221 | -209 | -3.60 | -64 | 473 | 614 |
| 2025 | 377 | -136 | -78 | -1.30 | -48 | 473 | 642 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
The core business works: fiscal 2025 revenue of $376.6 million, up 20 percent, 938,000 genes shipped, up 22 percent, more than 3,800 customers and 99 percent of revenue from repeat customers. In the quarter ended March 31, 2026 revenue grew 19.3 percent to $110.7 million and genes shipped rose 32 percent.
Manufacturing is measurably improving: gross margin of 36.6 percent in fiscal 2023, 42.6 percent in 2024, 50.7 percent in 2025 and 51.8 percent for the half year ended March 31, 2026 — with production fixed costs held broadly flat. This is the strongest evidence that the silicon-chip process scales.
Selling and administrative expenses exceed gross profit: $247.0 million against $191.0 million in fiscal 2025, and $76.1 million against $57.1 million in the quarter ended March 31, 2026. In that same quarter gross profit rose $11.1 million while selling and administrative expenses rose $12.4 million. The relief management has guided to for the second half of fiscal 2026 is still unproven.
The fall in net loss from $208.7 million in fiscal 2024 to $77.7 million in fiscal 2025 rests on a $48.8 million book gain from the May 2, 2025 sale of the data storage unit. Without that item the loss was about $126.5 million. In the half year ended March 31, 2026 the loss rose again to $74.5 million from $70.9 million.
No meaningful financial debt (debt-to-equity 0.03), equity of $455.1 million and $171.7 million of cash and short-term investments as of March 31, 2026 — set against roughly $30 million of cash outflow per quarter and an at-the-market program of up to $200 million available since June 18, 2026.
About $5.62 billion of market value (data as of July 26, 2026) stands against $409.5 million of annual revenue and $359.9 million of tangible book value — roughly 13 times revenue and 15 times tangible substance, without earnings. The price assumes the cost curve breaks before the cash does.
Twist Bioscience has a technically convincing product, a gross margin that has risen for three straight years and a debt-free balance sheet — but not yet a business model that turns 20 percent growth into profit: selling and administrative expenses alone cost more in fiscal 2025 than the entire gross profit delivered, and the seemingly halved loss owes itself to a one-time sale. Not investment advice.
- Origin: our in-house stock scanner, list "Richard Moglen: 1 Week Top Performers" (U.S. selection), rank 12 of 28 hits, RS rating 96, as of July 25, 2026. The list is recalculated daily.
- Data as of: SEC filings through the Form 10-Q for the quarter ended March 31, 2026 (filed May 4, 2026) plus the Form S-3ASR of June 18, 2026; market data as of July 26, 2026 (closing price July 24, 2026). The next quarterly report, for the quarter ended June 30, 2026, was not available at the time of writing.
- Easily confused: the DNA data storage business has not belonged to Twist since May 2, 2025 — it is now the standalone Atlas Data Storage, Inc., in which Twist holds only a minority stake. The earlier patent dispute with Agilent Technologies has been settled; the fiscal 2025 annual report lists Agilent only as a competitor.
About the Company
Twist Bioscience Corporation fertigt und verkauft synthetische DNA-basierte Produkte. Das Unternehmen bietet synthetische Gene und Genfragmente für die Produktentwicklung in den Bereichen Therapeutika, Diagnostik, Chemikalien/Materialien, Lebensmittel/Landwirtschaft, Datenspeicherung und verschiedene Anwendungen in der akademischen Forschung…
| Employees | 979 |
|---|---|
| Headquarters | South San Francisco, CA |
| Address | 681 Gateway Boulevard, 94080 South San Francisco, United States |
| Phone | 800 719 0671 |
| Website | twistbioscience.com |
| IPO Date | 31. Oct 2018 |
| ISIN | US90184D1000 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Emily Marine Leproust Ph.D. | Co-Founder, Board Chair & CEO | 1973 |
| Patrick John Finn Ph.D. | President & COO | 1972 |
| Adam Laponis | Chief Financial Officer | 1977 |
| Dennis Cho J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Paula Green | Senior Vice President of Human Resources | 1968 |
| Robert F. Werner | VP & Chief Accounting Officer | 1973 |
| Siyuan Chen | Chief Technology Officer | – |
| Michael Fero Ph.D. | Chief Information Officer | – |
| Colby Souders Ph.D. | Chief Scientific Officer | – |
| Nicole Moreno | Senior Vice President of Sales & Support | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 23. Jul 2026 | Finn Patrick John | President and COO | Sell | 2,238 | 93.89 | 210,133 |
| 9. Jul 2026 | Laponis Adam | Chief Financial Officer | Sell | 2,399 | 94.33 | 226,307 |
| 22. Apr 2026 | Emily M Leproust | CEO | Sell | 8,061 | 65.29 | 526,303 |
| 21. Apr 2026 | Emily M Leproust | CEO | Sell | 1,610 | 65.01 | 104,666 |
| 17. Apr 2026 | Adam Laponis | CFO | Sell | 4,000 | 60.00 | 240,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.